4.8 Review

Developmental origins and emerging therapeutic opportunities for childhood cancer

Journal

NATURE MEDICINE
Volume 25, Issue 3, Pages 367-376

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41591-019-0383-9

Keywords

-

Funding

  1. Career Award for Medical Scientist from Burroughs Wellcome Fund
  2. Solving Kids' Cancer
  3. Cure Starts Now Foundation
  4. DIPG Collaborative
  5. National Institutes of Neurological Disorders and Stroke [R01NS092597]
  6. National Institutes of Health [DP1NS111132]
  7. Abbie's Army
  8. McKenna Claire Foundation
  9. Unravel Pediatric Cancer Foundation
  10. Alex's Lemonade Stand Foundation
  11. Maternal and Child Health Research Institute at Stanford
  12. Anne T. and Robert M. Bass Endowed Faculty Scholarship in Pediatric Cancer and Blood Diseases

Ask authors/readers for more resources

Cancer is the leading disease-related cause of death in children in developed countries. Arising in the context of actively growing tissues, childhood cancers are fundamentally diseases of dysregulated development. Childhood cancers exhibit a lower overall mutational burden than adult cancers, and recent sequencing studies have revealed that the genomic events central to childhood oncogenesis include mutations resulting in broad epigenetic changes or translocations that result in fusion oncoproteins. Here, we will review the developmental origins of childhood cancers, epigenetic dysregulation in tissue stem/precursor cells in numerous examples of childhood cancer oncogenesis and emerging therapeutic opportunities aimed at both cell-intrinsic and microenvironmental targets together with new insights into the mechanisms underlying long-term sequelae of childhood cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available